On March 25, Facebook (NASDAQ: FB) announced the acquisition of leading virtual reality company, Oculus, in a deal worth $2 billion. At the time, many people wondered what was running behind the social media giant’s leadership as the co-founder and CEO, Mark Zuckerberg, made the announcement. It was not clear how the virtual reality company […]
By offering 100% original and unmatched content by the best financial reporters, writers and bloggers in the business, EmergingGrowth.com is emerging as a leading digital financial media portal. Its services provide users, subscribers and advertisers with a variety of content and tools through a range of online, social media, mobile and other mobile outlets.
Our mission is to attribute the most recent global events related to the financial markets, the economy, and industry trends, to the equities that will be affected by them and provide our users sound data with which they can make educated investment decisions. EmergingGrowth.com breaks down the barriers between current events and the financial markets leaving investors with a clear view of the road ahead.
We level the playing field and help all individuals and organizations grow their wealth by offering ideas on Emerging Growth companies found nowhere else. The smaller companies that make the big ones bigger, have potentially more room to grow. That is where we focus our attention and it is reflected in our stories. We offer the most comprehensive tools and insight needed to make informed investment decisions.
Since its inception, EmergingGrowth.com has distinguished itself from other financial media companies with its sly approach to reading between the lines in order to locate that needle in the haystack. Subscribe today to see what EmergingGrowth.com has to offer.
More from Emerging Growth
By Lennox Yieke Eulogizing about capitalism has never been an easy task. Painful memories of how trillions of dollars have disappeared from the world economy through fraud and scandals, and not to mention injustices that will never get a mention in a courtroom, still linger. Understandably, some people take this prevailing economic system of choice […]
The Sony Corporation (NYSE: SNE) has a new blueprint for how we’re going to game in future. It recently announced the new PlayStation Now innovation, which will use the functionalities of the cloud for processing games, as opposed to the traditional boxes in your living room. The company expects this service to become available to […]
There is no better period in a year when 1-800-Flowers.com, Inc. (NASDAQ: FLWS) can be in the headlines than Valentine’s Day. It has been in the headlines over the last few days, but it’s not the way any business would want to appear. CNN.com reported this past Sunday that 1-800-Flowers spoiled Valentine’s Day for many […]
It’s been a little over a year since I wrote an article here at Emerging Growth about why investors should consider Arrow Financial Corporation (NASDAQ: AROW) because of having a large percentage of insider activity going on. Since then, Arrow’s stock price has remained almost the same, rising by just over 5 percent. However, it […]
At one point, Mitcham Industries, Inc. (NASDAQ: MIND) was making headlines as one of the most promising emerging growth stocks. Its fortunes took a turn for the worse as the company’s quarterly earnings failed to live up to expectations. This saw a number of investors dumping the stock. There is, however, a strong reason to […]
I just saw this commercial on youtube. I thought it would be nice to post for my tech followers. I’ve got serious concerns about innovation and more importantly strategic partners with apple.
It’s been a while since the last article in the dividend investing series, but we’re back with this series and hope to make it more frequent. In this edition, we’ll examine a small-cap dividend stock that you can consider for a dividend reinvestment plan, or DRIP for short. Before we discuss the company in question, […]
Many biotech players have slated 2014 as the year to accomplish goals, ranging from announcement of results from clinical trials to submitting their drug candidates to the FDA for review and possible approval. These sorts of developments will give investors an idea regarding the direction biotech companies are headed. Therefore, I thought I should bring […]
As we wave goodbye to a glorious 2013 for the stock market and welcome the New Year, many investors are gathering their New Year investment goals and trying to determine this year’s top sectors and stocks. Aside from the stock market, we saw oil prices gain only 7 percent on the year, while the S&P […]
If you’re an avid follower of investment guru Warren Buffet, you’ll probably have heard this quote: “The 19th century belonged to England, the 20th century belonged to the U.S., and the 21st century belongs to China. Invest accordingly.” As such, whenever value investors come across publicly traded (U.S. traded especially) Chinese companies, it could be […]
Over two weeks into 2014, the market appears to be correcting as investors lock in profits from an outstanding 2013 market. It is still too early to tell if we are beginning a significant correction and, as I have said in previous articles, gaining a buying opportunity or dollar cost averaging. As we wait for […]
Like many small-cap biotech companies, Cempra, Inc. (NASDAQ: CEMP) is a clinical stage company with its focus set on developing antibiotics to treat drug-resistant bacterial infections. First thing to note is that this company is in a somewhat difficult business. Developing treatments for infections that aren’t drug-resistant is difficult. If this company has the right […]